NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Operating Income Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual operating income in 2023 was -17.77 Million CAD , up 22.11% from previous year.
NervGen Pharma Corp.'s latest quarterly operating income in 2024 Q2 was -6 Million CAD , down -20.01% from previous quarter.
NervGen Pharma Corp. reported an annual operating income of -22.82 Million CAD in 2022, down -77.39% from previous year.
NervGen Pharma Corp. reported an annual operating income of -12.86 Million CAD in 2021, down -15.01% from previous year.
NervGen Pharma Corp. reported a quarterly operating income of -6 Million CAD for 2024 Q2, down -20.01% from previous quarter.
NervGen Pharma Corp. reported a quarterly operating income of -4.63 Million CAD for 2023 Q2, down -1.41% from previous quarter.

Annual Operating Income Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Operating Income of NervGen Pharma Corp. (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	-17.77 Million CAD	22.11%
2022	-22.82 Million CAD	-77.39%
2021	-12.86 Million CAD	-15.01%
2020	-11.18 Million CAD	-13.41%
2019	-9.86 Million CAD	-626.14%
2018	-1.35 Million CAD	-11399.9%
2017	-11.81 Thousand CAD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-5 Million CAD	-2.57%
2024 Q2	-6 Million CAD	-20.01%
2023 Q2	-4.63 Million CAD	-1.41%
2023 Q1	-4.57 Million CAD	31.73%
2023 FY	-17.77 Million CAD	22.11%
2023 Q4	-4.87 Million CAD	-48.65%
2023 Q3	-3.27 Million CAD	29.29%
2022 Q1	-5.02 Million CAD	-21.52%
2022 FY	-22.82 Million CAD	-77.39%
2022 Q4	-6.69 Million CAD	-37.84%
2022 Q3	-4.85 Million CAD	22.55%
2022 Q2	-6.27 Million CAD	-24.89%
2021 FY	-12.86 Million CAD	-15.01%
2021 Q4	-4.13 Million CAD	-12.73%
2021 Q3	-3.66 Million CAD	-32.51%
2021 Q2	-2.76 Million CAD	-24.09%
2021 Q1	-2.23 Million CAD	49.47%
2020 Q3	-2.05 Million CAD	16.54%
2020 FY	-11.18 Million CAD	-13.41%
2020 Q1	-2.27 Million CAD	21.77%
2020 Q2	-2.45 Million CAD	-8.12%
2020 Q4	-4.41 Million CAD	-115.17%
2019 Q4	-2.9 Million CAD	-22.84%
2019 Q2	-1.56 Million CAD	48.09%
2019 Q1	-3.02 Million CAD	-293.71%
2019 Q3	-2.36 Million CAD	-50.72%
2019 FY	-9.86 Million CAD	-626.14%
2018 Q2	-64.35 Thousand CAD	-505.7%
2018 Q3	-515.54 Thousand CAD	-701.15%
2018 Q4	-767.96 Thousand CAD	-48.96%
2018 FY	-1.35 Million CAD	-11399.9%
2018 Q1	-10.62 Thousand CAD	0.0%
2017 FY	-11.81 Thousand CAD	0.0%

Peer Operating Income Comparison of NervGen Pharma Corp.

Name	Operating Income	Operating Income Difference
Arch Biopartners Inc.	-3.35 Million CAD	-429.832%
Covalon Technologies Ltd.	-4.48 Million CAD	-295.994%
Hemostemix Inc.	-2.33 Million CAD	-661.792%
Universal Ibogaine Inc.	497.15 Thousand CAD	3675.716%
Kane Biotech Inc.	-3.35 Million CAD	-429.481%
MedMira Inc.	-1.94 Million CAD	-814.29%
Marvel Biosciences Corp.	-2.31 Million CAD	-666.59%
XORTX Therapeutics Inc.	-6.38 Million CAD	-178.55%